Efficacy of intravenous immunoglobulin monotherapy in patients with cutaneous lupus erythematosus: Results of proof-of-concept study

Dermatology Reports

Volumn 7, Issue 1, 2015, Pages

  Ky, Christa ^a   Swasdibutra, Brian ^a   Khademi, Shaadi ^a   Desai, Sheetal ^a   Laquer, Vivian ^a   Grando, Sergei A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Case series; CLASI; Cutaneous lupus erythematosus; IVIg; Skindex 29

Indexed keywords

IMMUNOGLOBULIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND SEVERITY INDEX; CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND SEVERITY INDEX A; CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND SEVERITY INDEX D; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MONOTHERAPY; PHYSICIAN SUBJECTIVE ASSESSMENT OF IMPROVEMENT; PHYSICIAN SUBJECTIVE ASSESSMENT OF SEVERITY; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SKIN LUPUS ERYTHEMATOSUS; SKINDEX 29; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84925862792     PISSN: 20367392     EISSN: 20367406     Source Type: Journal    
DOI: 10.4081/dr.2015.5804     Document Type: Article

References (29)

1. Yu C, Chang C, Zhang J. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review. J Autoimmun 2013;41:34-45.
2. Kuhn A, Wenzel J, Weyd H. Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review. Clin Rev Allergy Immunol 2014;47:148-62.
3. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol 2011;65:e195-213.
4. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol 2011;65:e179-93.
5. Pelle MT. Issues and advances in the management and pathogenesis of cutaneous lupus erythematosus. Adv Dermatol 2006;22:55-65.
6. Luzi G, Bongiorno F, Paparo Barbaro S, Bruno G. Intravenous IgG: biological modulating molecules. J Biol Regul Homeost Agents 2009;23:1-9.
7. Gurcan HM, Ahmed AR. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Ann Pharmacother 2007;41:812-23.
8. Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 2004;15:46-50.
9. Genereau T, Chosidow O, Danel C, et al. High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 1999;135:1124-5.
10. Kreuter A, Gaifullina R, Tigges C, et al. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol 2009;145:244-8.
11. Kreuter A, Hyun J, Altmeyer P, Gambichler T. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol 2005;85:545- 7.
12. Espirito Santo J, Gomes MF, Gomes MJ, et al. Intravenous immunoglobulin in lupus panniculitis. Clin Rev Allergy Immunol 2010;38:307-18.
13. Lampropoulos CE, Hughes GR, DP DC. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol 2007;26:981-3.
14. De Pita O, Bellucci AM, Ruffelli M, et al. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus 1997;6:415-7.
15. Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin-clinical and serologic response. Lupus 1999;8:705-12.
16. Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 2011;147:203-8.
17. Seidling V, Hoffmann JH, Enk AH, Hadaschik EN. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol 2013;93:346-9.
18. Erceg A, Bovenschen HJ, van de Kerkhof PC, et al. Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus. J Am Acad Dermatol 2009;60:626-32.
19. Cutillas-Marco E, Marquina-Vila A, Grant W, et al. Vitamin D and cutaneous lupus erythematosus: effect of vitamin D replacement on disease severity. Lupus 2014. [Epub ahead of print].
20. Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005;125: 889-94.
21. Albrecht J, Werth VP. Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. Dermatol Ther 2007;20:93-101.
22. Bonilla-Martinez ZL, Albrecht J, Troxel AB, et al. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2008;144: 173-80.
23. Krathen MS, Dunham J, Gaines E, et al. the cutaneous lupus erythematosus disease activity and severity index: expansion for rheumatology and dermatology. Arthritis Rheum 2008;59:338-44.
24. Salphale P, Danda D, Chandrashekar L, et al. The study of cutaneous lupus erythematosus disease area and severity index in Indian patients with systemic lupus erythematosus. Lupus 2011;20:1510-7.
25. Piette EW, Foering KP, Chang AY, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol 2012;148:317- 22.
26. Braunstein I, Klein R, Okawa J, Werth VP. The IFN-regulated gene signature is elevated in SCLE and DLE and correlates with CLASI score. Br J Dermatol 2012;166:971- 5.
27. Cortes-Hernandez J, Avila G, Vilardell- Tarres M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 2012;14:R265.
28. Cortes-Hernandez J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol 2012;166:616- 23.
29. Coelho A, Souto MI, Cardoso CR, et al. Long term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus 2005;14:434-9.